--- title: Life Sciences description: >- Real-world evidence for life sciences teams—Pedestal Health delivers regulatory-grade RWE to accelerate R&D, approval, and commercialization. category: Page canonical_url: https://www.pedestalhealth.com/life-sciences/ source: Pedestal Health license: © 2026 Pedestal Health. All rights reserved. slug: life-sciences id: 2euoFAs2wlqXns44NZvJaz contentType: page --- # Evidence doesn't stop at the trial. Neither do your decisions. **Life Sciences** As questions evolve across the lifecycle, you need evidence that carries forward, not something you have to rebuild at every stage. From early development through regulatory review to market access and real-world use, you're making complex decisions under constant pressure to move faster without introducing risk. Questions evolve mid-development. Patient populations are harder to define than expected. Expectations from regulators and payers keep shifting. The challenge isn't generating more data. It's having evidence that reduces risk and moves decisions forward without forcing you to start over every time the next question comes up. ## Where decisions get harder The most important decisions aren't about broad populations or straightforward questions. They happen when things get more specific, less predictable, and harder to answer with traditional approaches. We help you navigate complex patient populations defined by clinical, biological, or treatment characteristics that don't show up clearly in standard datasets. When trials don't answer everything, you're able to evaluate subgroups, explore new indications, and understand why outcomes differ in real-world use. This becomes even more critical with therapies that don't fit clean models, including rare diseases, specialty drugs, and treatments with highly variable response, bridging the gap between controlled trial data and real-world outcomes, so decisions reflect how care actually happens. And when decisions need to be made – whether to move forward or pause a program, invest in a new indication, or defend value to regulators and payers – you're able to move forward with evidence that reduces uncertainty, even when information is incomplete. This is where a different approach becomes critical. ![Confident Woman Smiling in Urban Setting | Pedestal Health (diagonal)](https://images.ctfassets.net/h4s3ip99qawo/4iCXDo506jvj1WRKdmZYol/a1d0baeff2246413dec306bef6a6380f/iStock-1385744704.jpg) ## How that translates into action ### Design trials with more confidence Use longitudinal data and real-world insight to define patient populations, endpoints, and feasibility based on how care actually happens, not assumptions. ### Answer new questions without restarting work Extend and reuse existing data and evidence to evaluate subpopulations, explore new indications, and respond to evolving questions without rebuilding from scratch. ### Support regulatory and market access decisions with consistent evidence Generate evidence that holds up across submissions, payer discussions, and clinical use without conflicting results or revalidation at every stage. ### Extend evidence beyond approval Continue generating real-world insight post-launch to support safety, outcomes tracking, and long-term value demonstration. ## What this looks like in real life You're able to move beyond broad assumptions and answer more specific, higher-value questions, such as: ### Which patient subgroups actually respond to a therapy beyond initial inclusion criteria ### Whether a therapy could be effective in an adjacent or previously unstudied indication ### How to support external control arms when randomized trials aren't feasible ### What long-term outcomes and safety look like in real-world settings ### Why treatment response varies across different patient populations ### How to fill gaps when trials didn't capture the full picture ## Built for the decisions that aren't straightforward *What this allows you to do* Most approaches are optimized to generate large volumes of data. Ours is designed to generate the right evidence – especially when patient populations are complex and questions aren't straightforward. - Defined patient cohorts, not just broad populations - Longitudinal data grounded in real-world care - Evidence that evolves as questions change - Proven ability to support complex therapies and high-stakes decisions - Move forward without restarting work - Reduce risk across development and commercialization - Maintain consistency across stakeholders - Get more value from every dataset and study ![Diverse Research Team Collaborating in Modern Laboratory Setting (diagonal)](https://images.ctfassets.net/h4s3ip99qawo/1yIcQFersX9atuf7Mv7xL1/edc8ddc52d4e97ef5d9d5f7ff13c7cb5/iStock-1441665084.jpg)